ProCE Banner Activity

Key HIV Studies Influencing My Practice Following CROI 2022—Dr. Daniel Kuritzkes and Dr. David Wohl

Multimedia
Hear from CCO’s expert faculty members as they present their insights on some of the most clinically relevant new data presented at CROI 2022, including prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.

Released: March 03, 2022

Expiration: March 02, 2023

No longer available for credit.

Share

Faculty

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

David A. Wohl

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Cepheid

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has reported that he has received funds for research support from Gilead Sciences, Merck, and ViiV Healthcare and consultant/advisor/speaker fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV Healthcare, and ViroStatics.

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

David A. Wohl, MD, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Gilead Sciences, Janssen, Merck, and ViiV.